Across TCGA pan-cancer cohorts, RD3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RD3 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher RD3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RD3 expression acts as an unfavorable survival marker, although some lineages such as LIHC show a favorable association.

SARC, SCLC, and SKCM are the cancer types where RD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.086	0.611	<.001	12	view →
SCLC	DFS	Median	All	0.178	0.631	.005	9	view →
SKCM	DFS	Median	II,III,IV	0.155	0.712	.001	9	view →
LIHC	DFS	Median	All	1.000	0.282	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RD3 tumor-vs-normal RNA expression · all RD3 data types